Q3 Results Spark After-Hours Surge In GMED, TNDM, ICUI, ORGO, SKIN, TXG

Several healthcare and life sciences stocks posted significant after-hours gains on Thursday, driven by strong third-quarter earnings and optimistic 2025 guidance revisions. Globus Medical (GMED) surged 24.37% after reporting robust Q3 results, including a 22.9% sales increase, and raising its 2025 revenue and non-GAAP EPS outlook, with the Nevro acquisition expected to be accretive. Tandem Diabetes Care (TNDM) rebounded 20.03% on a narrowed net loss and reaffirmed its $1.0 billion 2025 sales guidance, while Organogenesis Holdings (ORGO) climbed 19.28% with a 30.6% increase in net product revenue and higher 2025 projections. Beauty Health (SKIN), ICU Medical (ICUI), and 10x Genomics (TXG) also saw notable advances, reflecting broad positive investor reaction to improved financial performance and updated outlooks across the sector.

Analysis

A robust wave of third-quarter earnings reports and upwardly revised 2025 guidance spurred significant after-hours gains across several healthcare and life sciences stocks. Globus Medical (GMED) led the surge, climbing 24.37% after reporting a 22.9% year-over-year increase in worldwide net sales to $769.0 million and raising its 2025 revenue outlook to $2.86-$2.90 billion, with the Nevro acquisition now expected to be accretive to 2025 earnings. Non-GAAP EPS guidance was also substantially lifted to $3.75-$3.85.

Tandem Diabetes Care (TNDM) rebounded 20.03%, narrowing its GAAP net loss to $21.2 million and reaffirming its 2025 sales guidance of approximately $1.0 billion, despite noting a $10 million headwind from direct commercial operations transition. Organogenesis Holdings (ORGO) also saw a 19.28% increase, driven by a 30.6% rise in net product revenue to $150.5 million and higher 2025 net product revenue projections of $500.0-$525.0 million.

Other companies like Beauty Health (SKIN), ICU Medical (ICUI), and 10x Genomics (TXG) also posted gains, recovering from earlier declines, despite some reporting Q3 revenue contractions. ICU Medical, for instance, narrowed its GAAP net loss significantly to $3.4 million and revised its 2025 adjusted EPS guidance upwards to $7.35-$7.65, indicating improved operational efficiency. Similarly, 10x Genomics narrowed its net loss and provided Q4 revenue guidance suggesting sequential growth.

These positive market reactions highlight investor focus on forward-looking guidance and improvements in profitability metrics, such as narrowed losses and adjusted EPS, even when top-line growth may be challenged in the short term. The sector-wide optimism suggests a re-evaluation of growth trajectories and operational leverage for 2025.

Key Decisions for Investors

• Investors should prioritize companies demonstrating strong upward revisions in 2025 guidance, particularly those with clear pathways to earnings accretion like Globus Medical's Nevro acquisition.
• Evaluate companies that have narrowed net losses or improved adjusted EPS guidance, even if current quarter revenue growth is soft, as this signals operational improvements and potential inflection points.
• Monitor the impact of strategic transitions and international expansion efforts, such as Tandem Diabetes Care's direct commercial operations, on future revenue and profitability outlooks.